Jan A J G van den Brand1, Peter R van Dijk2, Julia M Hofstra2, Jack F M Wetzels2. 1. Department of Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands Jan.vandenBrand@radboudumc.nl. 2. Department of Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Abstract
BACKGROUND AND OBJECTIVES: Cyclophosphamide treatment improves renal survival in patients with idiopathic membranous nephropathy. However, use of cyclophosphamide is associated with cancer. The incidence of malignancies in patients with idiopathic membranous nephropathy was evaluated, and the cancer risk associated with cyclophosphamide use was estimated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients who attended the clinic were included prospectively from 1995 on. A crude incidence ratio for the occurrence of malignancy was calculated. Incidence ratios were subsequently standardized to potential confounders. Latency between cyclophosphamide therapy and the occurrence of cancer was estimated by stratifying for time since the start of treatment. Finally, Poisson regression was used to obtain a multiple adjusted incidence ratio and investigate the dose-response relationship between cyclophosphamide and cancer. RESULTS: Data were available for 272 patients; the mean age was 51 years, and 70% of the patients were men. Median follow-up was 6.0 years (interquartile range=3.6-9.5), and 127 patients were treated with cyclophosphamide. Cancer incidence was 21.2 per 1000 person-years in treated patients compared with 4.6 per 1000 person-years in patients who did not receive cyclophosphamide, resulting in crude and adjusted incidence ratios of 4.6 (95% confidence interval, 1.5 to 18.8) and 3.2 (95% confidence interval, 1.0 to 9.5), respectively. CONCLUSION: Cyclophosphamide therapy in idiopathic membranous nephropathy gives a threefold increase in cancer risk. For the average patient, this finding translates into an increase in annual risk from approximately 0.3% to 1.0%. The increased risk of malignancy must be balanced against the improved renal survival.
BACKGROUND AND OBJECTIVES:Cyclophosphamide treatment improves renal survival in patients with idiopathic membranous nephropathy. However, use of cyclophosphamide is associated with cancer. The incidence of malignancies in patients with idiopathic membranous nephropathy was evaluated, and the cancer risk associated with cyclophosphamide use was estimated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients who attended the clinic were included prospectively from 1995 on. A crude incidence ratio for the occurrence of malignancy was calculated. Incidence ratios were subsequently standardized to potential confounders. Latency between cyclophosphamide therapy and the occurrence of cancer was estimated by stratifying for time since the start of treatment. Finally, Poisson regression was used to obtain a multiple adjusted incidence ratio and investigate the dose-response relationship between cyclophosphamide and cancer. RESULTS: Data were available for 272 patients; the mean age was 51 years, and 70% of the patients were men. Median follow-up was 6.0 years (interquartile range=3.6-9.5), and 127 patients were treated with cyclophosphamide. Cancer incidence was 21.2 per 1000 person-years in treated patients compared with 4.6 per 1000 person-years in patients who did not receive cyclophosphamide, resulting in crude and adjusted incidence ratios of 4.6 (95% confidence interval, 1.5 to 18.8) and 3.2 (95% confidence interval, 1.0 to 9.5), respectively. CONCLUSION:Cyclophosphamide therapy in idiopathic membranous nephropathy gives a threefold increase in cancer risk. For the average patient, this finding translates into an increase in annual risk from approximately 0.3% to 1.0%. The increased risk of malignancy must be balanced against the improved renal survival.
Authors: Amanda J W Branten; Peggy W du Buf-Vereijken; Ina S Klasen; Frank H Bosch; Geert W Feith; Daan A Hollander; Jack F Wetzels Journal: J Am Soc Nephrol Date: 2004-11-24 Impact factor: 10.121
Authors: L B Travis; R E Curtis; B Glimelius; E J Holowaty; F E Van Leeuwen; C F Lynch; A Hagenbeek; M Stovall; P M Banks; J Adami Journal: J Natl Cancer Inst Date: 1995-04-05 Impact factor: 13.506
Authors: C Ponticelli; P Zucchelli; P Passerini; B Cesana; F Locatelli; S Pasquali; M Sasdelli; B Redaelli; C Grassi; C Pozzi Journal: Kidney Int Date: 1995-11 Impact factor: 10.612
Authors: C Talar-Williams; Y M Hijazi; M M Walther; W M Linehan; C W Hallahan; I Lubensky; G S Kerr; G S Hoffman; A S Fauci; M C Sneller Journal: Ann Intern Med Date: 1996-03-01 Impact factor: 25.391
Authors: C D Radis; L E Kahl; G L Baker; M C Wasko; J M Cash; A Gallatin; B L Stolzer; A K Agarwal; T A Medsger; C K Kwoh Journal: Arthritis Rheum Date: 1995-08
Authors: Jan A J G van den Brand; Piero Ruggenenti; Antonietta Chianca; Julia M Hofstra; Annalisa Perna; Barbara Ruggiero; Jack F M Wetzels; Giuseppe Remuzzi Journal: J Am Soc Nephrol Date: 2017-05-09 Impact factor: 10.121
Authors: Sasha Bernatsky; Rosalind Ramsey-Goldman; Murray B Urowitz; John G Hanly; Caroline Gordon; Michelle A Petri; Ellen M Ginzler; Daniel J Wallace; Sang-Cheol Bae; Juanita Romero-Diaz; Mary Anne Dooley; Christine A Peschken; David A Isenberg; Anisur Rahman; Susan Manzi; Søren Jacobsen; S Sam Lim; Ronald van Vollenhoven; Ola Nived; Diane L Kamen; Cynthia Aranow; Guillermo Ruiz-Irastorza; Jorge Sánchez-Guerrero; Dafna D Gladman; Paul R Fortin; Graciela S Alarcón; Joan T Merrill; Kenneth C Kalunian; Manuel Ramos-Casals; Kristjan Steinsson; Asad Zoma; Anca Askanase; Munther A Khamashta; Ian Bruce; Murat Inanc; Ann E Clarke Journal: Arthritis Care Res (Hoboken) Date: 2021-10-12 Impact factor: 5.178